#USA #Portland #Board of Directors #Araceli Biosciences #Christine Tsingos

Araceli Biosciences Welcomes Christine Tsingos to Its Board of Directors

On April 16, 2026, Araceli Biosciences revealed the exciting news of Christine A. Tsingos' appointment to its Board of Directors. Known for her extensive expertise as a public company executive, Christine brings over 30 years of rich experience that spans financial leadership, governance, and strategic growth to the table.

Following her tenure as Executive Vice President and Chief Financial Officer at Bio-Rad Laboratories from 2002 to 2019, Christine established a reputation for driving sustained growth and strategic expansion across various sectors, including capital strategy, treasury, investor relations, mergers and acquisitions, and information technology. Bill Cortelyou, the Chairman of the Board at Araceli, stated, "Christine brings deep financial, governance, and strategic leadership to Araceli at an important point in the company's growth. Her experience in scaling life sciences companies aids us in bolstering long-term value creation as we transition to our next phase."

Christine's pivotal roles have not been limited to Bio-Rad. She currently serves on the boards of Envista Holdings and Varex Imaging Corporation, and has previously served on the boards of Onto Innovation and Telesis Bio. Her academic credentials are equally impressive; she holds a Bachelor of Arts in International Studies from American University and an MBA in International Business from The George Washington University.

The addition of Christine Tsingos signifies a strategic move for Araceli Biosciences, particularly during this pivotal moment as the company focuses on advancing AI-driven, lab-in-the-loop drug discovery. Matt Beaudet, the CEO of Araceli, emphasized Christine's past experience in helping companies transition from standalone tools to integrated systems within modern lab infrastructures, underscoring the essential nature of her expertise as they scale operations.

In her own words, Christine reflected on Araceli's rapid momentum in a short span: "The company reflects the strength of its technology and a clear market need. Our focus now is on laying the foundation for scalable growth, and I am thrilled to contribute to this initiative."

About Araceli Biosciences

Araceli Biosciences is pioneering the future of biological discovery by introducing ultra-high throughput imaging solutions. These innovations empower researchers by providing richer data that accelerates decision-making throughout the drug discovery and life science research processes. As a company at the intersection of technology and science, the appointment of seasoned professionals like Christine Tsingos to its Board of Directors underscores Araceli's commitment to strengthening its governance and leadership as it navigates its exciting growth trajectory.

Through this strategic leadership appointment, Araceli Biosciences is positioned not only to respond adeptly to current market dynamics but also to innovate relentlessly, ensuring that their breakthroughs in drug discovery hold the potential for significant impact in the health sector in years to come.